Obviating much of the need for insulin therapy in type 2 diabetes mellitus: A re-assessment of insulin therapy’s safety profile

References

• Bradley D, Magkos F, Klein S. Effects of bariatric surgery on glucose homeostasis and type 2 diabetes. Gastroenterology. 2012;143:897–912.
   PubMedGoogle Scholar
• Wickremesekera K, Miller G, Naotunne TD, et al. Loss of insulin resistance after Roux-en-Y gastric bypass surgery: a time course study. Obes Surg. 2005 Apr;15(4):474–481.
   PubMed Web of Science ®Google Scholar
• Schwartz SS. Do many people with type 2 diabetes really need insulin? In: Draznin B, Low Wang CC, Rubin DJ, editors. Diabetes case studies. Alexandria, VA: American Diabetes Association; 2015b. p. 247–249.
   Google Scholar
• Del Prato S. Role of glucotoxicity and lipotoxicity in the pathophysiology of Type 2 diabetes mellitus and emerging treatment strategies. Diabetic Med. 2009;26:1185–1192.
   PubMed Web of Science ®Google Scholar
• Chiasson J. Early insulin use in type 2 diabetes: what are the cons? Diabetes Care. 2009;32(SUPPLEMENT 2):S270–S274.
   PubMed Web of Science ®Google Scholar
• Currie CJ, Johnson JA. The safety profile of exogenous insulin in people with type 2 diabetes: justification for concern. Diabetes Obes Metab. 2012;14:1–4.
   PubMed Web of Science ®Google Scholar
• Currie C, Poole C, Evans M, et al. Mortality and other important diabetes-related outcomes with insulin vs other antihyperglycemic therapies in type 2 diabetes. J Clin Endocrinol Metab. 2013;98:668–677.
   PubMed Web of Science ®Google Scholar
• Nolan CJ, Ruderman NB, Prentki M. Intensive insulin for type 2 diabetes: the risk of causing harm. Lancet Diabetes Endocrinol. 2013 Sep;1(1):9–10.
   PubMed Web of Science ®Google Scholar
• Yang X, Mei S, Gu H, et al. Exposure to excess insulin (glargine) induces type 2 diabetes mellitus in mice fed on a chow diet. J Endocrin. 2014;221:469–480.
   PubMed Web of Science ®Google Scholar
• Ismail-Beigi F, Moghissi E, Tiktin M, et al. Individualizing glycemic targets in type 2 diabetes mellitus: implications of recent clinical trials. Ann Intern Med. 2011;154:554–559.
   PubMed Web of Science ®Google Scholar
• Montori VM, Fernandez-Balsells M. Glycemic control in type 2 diabetes: time for an evidence-based about-face? Ann Intern Med. 2009;150:803–808.
   PubMed Web of Science ®Google Scholar
• Schwartz SS, Epstein S, Corkey BE, et al. The time is right for a new classification system for diabetes Rationale and implications of the b-cell–centric classification schema. Diabetes Care. 2016;39:179–186. doi:10.2337/dc15-1585.
   PubMed Web of Science ®Google Scholar
• Yudkin JS, Richter B, Gale EA. Intensified glucose lowering in type 2 diabetes: time for a reappraisal. Diabetologia. 2010;53:2079–2085.
   PubMed Web of Science ®Google Scholar
• Colayco DC, Niu F, McCombs JS, et al. A1C and cardiovascular outcomes in type 2 diabetes: a nested case-control study. Diabetes Care. 2011 Jan;34(1):77–83.
   PubMed Web of Science ®Google Scholar
• UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet. 1998;352:837–853.
   PubMed Web of Science ®Google Scholar
• Orchard TJ, Nathan DM, Zinman B, Writing Group for the DCCT/EDIC Research Group, et al. Association between 7 years of intensive treatment of type 1 diabetes and long-term mortality. JAMA. 2015 Jan 6;313(1):45–53. DOI:10.1001/jama.2014.16107.
   PubMed Web of Science ®Google Scholar
• Gerstein HC, Miller ME, Byington RP, Action to Control Cardiovascular Risk in Diabetes Study (ACCORD Group), et al. Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med. 2008;358:2545–2559.
   PubMed Web of Science ®Google Scholar
• Holden SE, Jenkins-Jones S, Morgan CL, et al. Glucose-lowering with exogenous insulin monotherapy in type 2 diabetes: dose association with all-cause mortality, cardiovascular events and cancer. Diabetes Obes Metab. 2015 Apr;17(4):350–362. doi:10.1111/dom.12412. Epub 2014 Dec 10.
   PubMed Web of Science ®Google Scholar
• ORIGIN Trial Investigators, Gerstein HC, Bosch J, et al. Basal insulin and cardiovascular and other outcomes in dysglycemia. N Engl J Med. 2012;367:319–328.
   Google Scholar
• Currie CJ, Peters JR, Tynan A, et al. Survival as a function of HbA1c in people with type 2 diabetes: a retrospective cohort study. Lancet. 2010;375:481–489.
   PubMed Web of Science ®Google Scholar
• the Action to Control Cardiovascular Risk in Diabetes Investigators, Riddle MC, Ambrosius WT, Brillon DJ. Epidemiologic relationships between A1C and all-cause mortality during a median 3.4-year follow-up of glycemic treatment in the ACCORD trial. Diabetes Care. 2010;33(5):983–990.
   PubMed Web of Science ®Google Scholar
• Smooke S, Horwich TB, Fonarow GC, et al. Insulin-treated diabetes is associated with a marked increase in mortality in patients with advanced heart failure. Am Heart J. 2005;149:168–174.
   PubMed Web of Science ®Google Scholar
• Ertek S, Cetinkalp S. Is there U-turn from insulin back to pills in diabetes? Curr Vasc Pharmacol. 2014;12(4):617–626.
   PubMed Web of Science ®Google Scholar
• Kelly CT, Mansoor J, Dohm GL, et al. Hyperinsulinemic syndrome: the metabolic syndrome is broader than you think. Surgery. 2014;156:405–411.
   PubMed Web of Science ®Google Scholar
• Lebovitz HE. Insulin: potential negative consequences of early routine use in persons with type 2 diabetes. Diabetes Care. 2011;34(Suppl 2):S225–S230.
   PubMed Web of Science ®Google Scholar
• Matteucci E, Giampietro O, Covolan V, et al. Insulin administration: present strategies and future directions for a noninvasive (possibly more physiological) delivery. Drug Des Devel Ther. 2015 Jun;17(9):3109–3118. doi:10.2147/DDDT.S79322. eCollection 2015.
   Web of Science ®Google Scholar
• Draznin B, Miles P, Kruszynska Y, et al. Effects of insulin on prenylation as a mechanism of potentially detrimental influence of hyperinsulinemia. Endocrinology. 2000;141:1310–1316.
   PubMed Web of Science ®Google Scholar
• Madonna R, De Caterina R. Prolonged exposure to high insulin impairs the endothelial P13-kinase/Akt/nitric oxide signalling. Thromb Haemost. 2009 Feb;101(2):345–350.
   PubMed Web of Science ®Google Scholar
• Bowker SL, Majumdar SR, Veugelers P, et al. Increased cancer-related mortality for patients with type 2 diabetes who use sulfonylureas or insulin. Diabetes Care. 2006;29:254–258.
   PubMed Web of Science ®Google Scholar
• Draznin B. Mechanism of the mitogenic influence of hyperinsulinemia. Diabetol Metab Syndr. 2011;3:10.
   PubMed Web of Science ®Google Scholar
• Gallagher EJ, LeRoith D. Obesity and diabetes: the Increased risk of cancer and cancer-related mortality. Physiol Rev. 2015 Jul;95(3):727–748. doi:10.1152/physrev.00030.2014.
   PubMed Web of Science ®Google Scholar
• Karlstad O, Starup-Linde J, Vestergaard P, et al. Use of insulin and insulin analogs and risk of cancer – systematic review and meta-analysis of observational studies. Curr Drug Saf. 2013;8:333–348.
   PubMedGoogle Scholar
• Muntoni S, Muntoni S. Insulin resistance: pathophysiology and rationale for treatment. Ann Nutr Metab. 2011;58:25–36.
   PubMed Web of Science ®Google Scholar
• Yarchoan M, Arnold SE. Repurposing diabetes drugs for brain insulin resistance in Alzheimer disease. Diabetes. 2014 Jul;63(7): 2253–2261. doi:10.2337/db14-0287. Epub 2014 Jun 15.
   PubMed Web of Science ®Google Scholar
• Verdile G, Keane KN, Cruzat VF, et al. Inflammation and oxidative stress: the molecular connectivity between insulin resistance, obesity, and Alzheimer’s disease. Mediators Inflamm. 2015;2015: 105828. doi:10.1155/2015/105828. Epub 2015 Nov 26.
   PubMed Web of Science ®Google Scholar
• Kleinridders A, Ferris HA, Cai W, et al. Insulin action in brain regulates systemic metabolism and brain function. Diabetes. 2014 Jul;63(7): 2232–2243. doi:10.2337/db14-0568. Epub 2014 Jun 15.
   PubMed Web of Science ®Google Scholar
• Schwartz S, Fabricatore AN, Diamond A. Weight reduction in diabetes. In: Ahmad SI, editor. Diabetes: an old disease, a new insight. New York, NY: Springer Science+Business Media LLC; 2012. p. 438–458.
   Google Scholar
• Schwartz S, Herman M. Revisiting weight reduction and management in the diabetic patient: Novel therapies provide new strategies. Postgrad Med. 2015a; Early Online: 1–14. doi:10.1080/00325481.2015.1043182.
   Web of Science ®Google Scholar
• Veneman TF, Erkelens DW. Hypoglycemia Unawareness in Noninsulin-Dependent Diabetes Mellitus. J Clin Endocrinol Metab. 1997 June 1;82(6):1682–1684.
   PubMed Web of Science ®Google Scholar
• Chico A. The continuous glucose monitoring system is useful for detecting unrecognized hypoglycemias in patients with type 1 and type 2 diabetes but is not better than frequent capillary glucose measurements for improving metabolic control. Diabetes Care. 2003;26:1153–1157.
   PubMed Web of Science ®Google Scholar
• Holman RR, Paul SK, Bethel MA, et al. 10-year follow-up of intensive glucose control in type 2 diabetes. N Engl J Med. 2008;359:1577–1589.
   PubMed Web of Science ®Google Scholar
• Bonds DE, Miller ME, Bergenstal RM, et al. The association between symptomatic, severe hypoglycaemia and mortality in type 2 diabetes: retrospective epidemiological analysis of the ACCORD study. BMJ. 2010;340:b4909. doi:10.1136/bmj.b4909.
   PubMed Web of Science ®Google Scholar
• Duckworth W, Abraira C, Moritz T, et al. Glucose control and vascular complications in veterans with type 2 diabetes. N Engl J Med. 2009;360:129–139.
   PubMed Web of Science ®Google Scholar
• Hayward RA, Reaven PD, Wiitala WL, et al. Follow-up of glycemic control and cardiovascular outcomes in type 2 diabetes. N Engl J Med. 2015;372:2197–2206.
   PubMed Web of Science ®Google Scholar
• Patel A, MacMahon S, Chalmers J, The ADVANCE Collaborative Group, et al. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med. 2008;358:2560–2572.
   PubMed Web of Science ®Google Scholar
• Skyler JS, Bergenstal R, Bonow RO, et al. Intensive glycemic control and the prevention of cardiovascular events: implications of the ACCORD, ADVANCE, and VA diabetes trials. A position statement of the American diabetes association and a scientific statement of the American college of cardiology foundation and the American heart association. Diabetes Care. 2009;32:187–192.
   PubMed Web of Science ®Google Scholar
• Mellbin LG, Malmberg K, Norhammar A, for the DIGAMI 2 Investigators, et al. Prognostic implications of glucose-lowering treatment in patients with acute myocardial infarction and diabetes: experiences from an extended follow-up of the Diabetes Mellitus Insulin-Glucose Infusion in Acute Myocardial Infarction (DIGAMI) 2 study. Diabetologia. 2011;54:1308–1317.
   PubMed Web of Science ®Google Scholar
• Anselmino M, Ohrvik J, Malmberg K, et al. Glucose lowering treatment in patients with coronary artery disease is prognostically important not only in established but also in newly detected diabetes mellitus: a report from the Euro Heart Survey on Diabetes and the Heart. Eur Heart J. 2008;29(2):177–184. Epub 2007 Dec 21.
   PubMed Web of Science ®Google Scholar
• Margolis DJ, Hoffstad O, Strom BL. Association between serious ischemic cardiac outcomes and medications used to treat diabetes. Pharmaco-Epidemiol Drug Saf. 2008;17:753–759.
   PubMed Web of Science ®Google Scholar
• Groop PH, Forsblom C, Thomas MC. Mechanisms of disease: Pathway-selective insulin resistance and microvascular complications of diabetes. Nat Clin Pract Endocrinol Metab. 2005 Dec;1(2):100–110.
   PubMedGoogle Scholar
• Draznin B. Mitogenic action of insulin: friend, foe or ‘frenemy’? Diabetologia. 2010;53:229–233.
   PubMed Web of Science ®Google Scholar
• Litvinova L, Atochin DN, Fattakhov N, et al. Nitric oxide and mitochondria in metabolic syndrome. Front Physiol. 2015;6:20.
   PubMed Web of Science ®Google Scholar
• Holden SE, Currie CJ. Endogenous hyperinsulinaemia and exogenous insulin: A common theme between atherosclerosis, increased cancer risk and other morbidities. Atherosclerosis. 2012;222:26–28.
   PubMed Web of Science ®Google Scholar
• Wang X, Yu Z, Zhang B, et al. The injurious effects of hyperinsulinism on blood vessels. Cell Biochem Biophys. 2014;69:213–218.
   PubMed Web of Science ®Google Scholar
• Nandish S, Bailon O, Wyatt J, et al. Vasculotoxic effects of insulin and its role in atherosclerosis: what is the evidence? Curr Atheroscler Rep. 2011;13:123–128.
   PubMed Web of Science ®Google Scholar
• Reaven GM. Insulin resistance: A bit player to centre stage. CMAJ. 2011;183:536–537.
   PubMed Web of Science ®Google Scholar
• Reaven GM. The kidney: an unwilling accomplice in syndrome X. Am J Kidney Dis. 1997;30:928–931.
   PubMed Web of Science ®Google Scholar
• Tseng CH. Exogenous insulin use and hypertension in adult patients with type 2 diabetes mellitus. Arch Intern Med. 2006 Jun 12;166(11):1184–1189.
   PubMedGoogle Scholar
• Dormandy JA, Charbonnel B, Eckland DJ, et al. Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial. Lancet. 2005 Oct 8;366(9493):1279–1289.
   PubMed Web of Science ®Google Scholar
• Ferrannini E, DeFronzo RA. Impact of glucose-lowering drugs on cardiovascular disease in type 2 diabetes. Eur Heart J. 2015;36(34):2288–2296.
   PubMed Web of Science ®Google Scholar
• Bell DS. Focusing on cardiovascular disease in type 2 diabetes mellitus: an introduction to bromocriptine QR. Postgrad Med. 2012 Sep;124(5):121–135.
   PubMed Web of Science ®Google Scholar
• Chiasson JL, Josse RG, Gomis R, et al. Acarbose for prevention of type 2 diabetes mellitus: the STOP-NIDDM randomized trial. Lancet. 2002;359(9323):2072–2077.
   PubMed Web of Science ®Google Scholar
• Standl E, Theodorakis MJ, Erbach M, et al. On the potential of acarbose to reduce cardiovascular disease. Cardiovasc Diabetol. 2014 Apr;16(13):81.
   Web of Science ®Google Scholar
• Cobble ME, Frederich R. Saxagliptin for the treatment of type 2 diabetes mellitus: assessing cardiovascular data. Cardiovasc Diabetol. 2012;11:6. doi:10.1186/1475-2840-11-6.
   PubMed Web of Science ®Google Scholar
• Scirica BM, Bhatt DL, Braunwald E, et al. Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus. N Engl J Med. 2013;369:1317–1326. (SAVOR-TIMI 53 Study)
   PubMed Web of Science ®Google Scholar
• Green JB, Bethel MA, Armstrong PW, et al. Effect of sitagliptin on cardiovascular outcomes in type 2 diabetes. N Engl J Med. 2015;373:232–242. (TECOS Study)
   PubMed Web of Science ®Google Scholar
• the EXAMINE Investigators, Zannad F, Cannon CP, Cushman WC. Heart failure and mortality outcomes in patients with type 2 diabetes taking alogliptin versus placebo in EXAMINE: a multicentre, randomised, double-blind trial. Lancet. 2015;385(9982):2067–2076.
   PubMed Web of Science ®Google Scholar
• Pfeffer MA, Claggett B, Diaz R, et al. Lixisenatide in patients with type 2 diabetes and acute coronary syndrome. N Engl J Med. 2015;373:2247–2257.
   PubMed Web of Science ®Google Scholar
• Best JH, Hoogwerf BJ, Herman WH, et al. Risk of cardiovascular disease events in patients with type 2 diabetes prescribed the glucagon-like peptide 1 (GLP-1) receptor agonist exenatide twice daily or other glucose-lowering therapies: a retrospective analysis of the LifeLink database. Diabetes Care. 2011;34:90–95.
   PubMed Web of Science ®Google Scholar
• Marso SP, Poulter NR, Nissen SE, et al. Design of the liraglutide effect and action in diabetes: Evaluation of cardiovascular outcome results (LEADER) trial. Am Heart J. 2013;166:823–830.e5.
   PubMed Web of Science ®Google Scholar
• Marx N, Rosenstock J, Kahn SE, et al. Design and baseline characteristics of the CARdiovascular outcome trial of LINAgliptin versus glimepiride in type 2 diabetes (CAROLINA®). Diab Vasc Dis Res. 2015 May;12(3):164–174.
   PubMed Web of Science ®Google Scholar
• Zinman B, Wanner C, Lachin JM, et al. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med. 2015;373(22):2117–2128.
   PubMed Web of Science ®Google Scholar
• Inzucchi SE, Zinman B, Wanner C, et al. SGLT-2 inhibitors and cardiovascular risk: proposed pathways and review of ongoing outcome trials. Diab Vasc Dis Res. 2015a Mar;12(2):90–100.
   PubMed Web of Science ®Google Scholar
• Jayawardene D, Ward GM, O’Neal DN, et al. New treatments for type 2 diabetes: cardiovascular protection beyond glucose lowering? Heart Lung Circ. 2014 Nov;23(11):997–1008.
   PubMed Web of Science ®Google Scholar
• Usher JR, Drucker DJ. Cardiovascular biology of the incretin system. Endocr Rev, 2012 April;33(2):187–215.
   PubMed Web of Science ®Google Scholar
• Jadzinsky M, Pfützner A, Paz-Pacheco E, et al. Saxagliptin given in combination with metformin as initial therapy improves glycaemic control in patients with type 2 diabetes compared with either monotherapy: a randomized controlled trial. Diabetes Obes Metab. 2009;11:611–622.
   PubMed Web of Science ®Google Scholar
• Pratley R, Nauck M, Bailey T, et al. One year of liraglutide treatment offers sustained and more effective glycaemic control and weight reduction compared with sitagliptin, both in combination with metformin, in patients with type 2 diabetes: a randomised, parallel-group, open-label trial. Int J Clin Pract. 2011;65:397–407.
   PubMed Web of Science ®Google Scholar
• Ratner R, Han J, Nicewarner D, et al. Cardiovascular safety of exenatide BID: an integrated analysis from controlled clinical trials in participants with type 2 diabetes. Cardiovasc Diabetol. 2011;10:22.
   PubMed Web of Science ®Google Scholar
• Weng J, Li Y, Xu W, et al. Effect of intensive insulin therapy on beta cell function and glycaemic control in patients with newly diagnosed type 2 diabetes: a multicentre randomised parallel group trial. Lancet. 2008;371:1753–1760.
   PubMed Web of Science ®Google Scholar
• Defronzo RA, Tripathy D, Schwenke DC, et al. ACT NOW Study. Prevention of diabetes with pioglitazone in ACT NOW: physiologic correlates. Diabetes. 2013;62:3920–3926.
   PubMed Web of Science ®Google Scholar
• Gastaldelli A, Ferrannini E, Miyazaki Y, et al. Thiazolidinediones improve beta-cell function in type 2 diabetic patients. Am J Physiol Endocrinol Metab. 2007;292:E871–E883.
   PubMed Web of Science ®Google Scholar
• Knowler WC, Barrett-Connor E, Fowler SE, et al. Reduction in the incidence of type 2 diabetes with life- style intervention or metformin. N Engl J Med. 2002;346:393–403.
   PubMed Web of Science ®Google Scholar
• Armato J, DeFronzo R, Abdul-Ghani M, et al. Successful treatment of prediabetes in clinical practice: targeting insulin resistance and β-Cell Dysfunction. Endocr Pract. 2012;18:342–350.
   PubMed Web of Science ®Google Scholar
• Astrup A, Rössner S, Van Gaal L, NN8022-1807 Study Group, et al. Effects of liraglutide in the treatment of obesity: a randomised, double-blind, placebo-controlled study. Lancet. 2009;374:1606–1616.
   PubMed Web of Science ®Google Scholar
• Bunck MC, Cornér A, Eliasson B, et al. Effects of exenatide on measures of β-cell function after 3 years in metformin-treated patients with type 2 diabetes. Diabetes Care. 2011;34(9):2041–2047.
   PubMed Web of Science ®Google Scholar
• Triplitt C, DeFronzo RA. Exenatide: first in class incretin mimetic for the treatment of type 2 diabetes mellitus. Expert Rev Endocr Metab. 2006;1:329–341.
   PubMedGoogle Scholar
• Rosenstock J, Klaff LJ, Schwartz S, et al. Effects of exenatide and lifestyle modification on body weight and glucose tolerance in obese subjects with and without prediabetes. Diabetes Care. 2010;33:1173–1175.
   PubMed Web of Science ®Google Scholar
• Nonaka K, Kakikawa T, Sato A, et al. Efficacy and safety of sitagliptin monotherapy in Japanese patients with type 2 diabetes. Diabetes Res Clin Pract. 2008;79:291–298.
   PubMed Web of Science ®Google Scholar
• Rosenstock J, Sankoh S, List JF. Glucose-lowering activity of the dipeptidyl peptidase-4 inhibitor saxagliptin in drug-naïve patients with type 2 diabetes. Diabetes Obes Metab. 2008;10:376–386.
   PubMed Web of Science ®Google Scholar
• Ahima RS. EDITORIAL: rethinking the definition of diabetes for precision medicine. Mol Endocrinol. 2015 Mar;29(3):335–337.
   PubMed Web of Science ®Google Scholar
• Chen J, Couto FM, Minn AH, et al. Exenatide inhibits beta-cell apoptosis by decreasing thioredoxin-interacting protein. Biochem Biophys Res Commun. 2006;346:1067–1074.
   PubMed Web of Science ®Google Scholar
• Mu J, Woods J, Zhou YP, et al. Chronic inhibition of dipeptidyl peptidase-4 with a sitagliptin analog preserves pancreatic beta-cell mass and function in a rodent model of type 2 diabetes. Diabetes. 2006;55:1695–1704.
   PubMed Web of Science ®Google Scholar
• Bojsen-Møller KN, Jacobsen SH, Dirksen C, et al. Accelerated protein digestion and amino acid absorption after Roux-en-Y gastric bypass. Am J Clin Nutr. 2015 Sep;102(3):600–607.
   PubMed Web of Science ®Google Scholar
• Turner RC, Cull CA, Frighi V, UK Prospective Diabetes Study (UKPDS) Group, et al. Glycemic control with diet, sulfonylurea, metformin, or insulin in patients with type 2 diabetes mellitus: progressive requirement for multiple therapies (UKPDS 49). JAMA. 1999;281:2005–2012.
   PubMed Web of Science ®Google Scholar
• Abdul-Ghani MA, Puckett C, Triplitt C, et al. Initial combination therapy with metformin, pioglitazone and exenatide is more effective than sequential add-on therapy in subjects with new-onset diabetes. Results from the Efficacy and Durability of Initial Combination Therapy for Type 2 diabetes (EDICT): a randomized trial. Diabetes Obes Metab. 2014 Nov 26;doi:10.1111/dom.12417. [Epub ahead of print].
   Web of Science ®Google Scholar
• Campbell JE, Drucker DJ. Pharmacology, physiology, and mechanisms of incretin hormone action. Cell Metabolism. 2013;17:819–837. doi:10.1016/j.cmet.2013.04.008.
   PubMed Web of Science ®Google Scholar
• Jellinger PS. Focus on incretin-based therapies: targeting the core defects of type 2 diabetes. Postgrad Med. 2011 Jan;123(1):53–65.
   PubMed Web of Science ®Google Scholar
• Defronzo RA. Banting lecture. From the triumvirate to the ominous octet: a new paradigm for the treatment of type 2 diabetes mellitus. Diabetes. 2009 Apr;58(4):773–795.
   PubMed Web of Science ®Google Scholar
• Handelsman Y, Bloomgarden ZT, Grunberger G, et al. American association of clinical endocrinologists and American college of endocrinology - clinical practice guidelines for developing a diabetes mellitus comprehensive care plan - 2015. Endocr Pract. 2015 Apr 1;21(0):1–87. DOI:10.4158/EP15672.GL.
   PubMedGoogle Scholar
• Rizzo M, Nikolic D, Banach M, et al. Incretin-based therapies, glucometabolic health and endovascular inflammation. Curr Pharm Des. 2014;20(31):4953–4960. Review.
   PubMed Web of Science ®Google Scholar
• Handelsman Y, Henry RR, Bloomgarden ZT, et al. AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS AND AMERICAN COLLEGE OF ENDOCRINOLOGY POSITION STATEMENT ON THE ASSOCIATION OF SGLT-2 INHIBITORS AND DIABETIC KETOACIDOSIS. Endocr Pract. 2016 Jun 1. [Epub ahead of print].
   Web of Science ®Google Scholar
• Davidson MB. Pioglitazone (Actos) and bladder cancer: legal system triumphs over the evidence. J Diabetes Complications. 2016 Apr 11;pii: S1056-8727(16)30103-9. doi:10.1016/j.jdiacomp.2016.04.004. [Epub ahead of print].
   PubMedGoogle Scholar
• Lewis JD, Habel LA, Quesenberry CP, et al. Pioglitazone use and risk of bladder cancer and other common cancers in persons with diabetes. JAMA. 2015 Jul 21;314(3):265–277.
   PubMed Web of Science ®Google Scholar
• Garber A, King AB, Del Prato S, et al. Insulin degludec, an ultra-longacting basal insulin, versus insulin glargine in basal-bolus treatment with mealtime insulin aspart in type 2 diabetes (BEGIN Basal-Bolus Type 2): a phase 3, randomized, open-label, treat-to-target non-inferiority trial. Lancet. 2012;379:1498–1507.
   PubMed Web of Science ®Google Scholar
• Raccah D, Lin J, Wang E, et al. Once-daily prandial lixisenatide versus once-daily rapid-acting insulin in patients with type 2 diabetes mellitus insufficiently controlled with basal insulin: analysis of data from five randomized, controlled trials. J Diabetes Complicat. 2014 Jan-Feb;28(1):40–44.
   PubMed Web of Science ®Google Scholar
• Arnolds S, Dellweg S, Clair J, et al. Further improvement in postprandial glucose control with addition of exenatide or sitagliptin to combination therapy with insulin glargine and metformin: a proof-of-concept study. Diabetes Care. 2010 Jul;33(7):1509–1515.
   PubMed Web of Science ®Google Scholar
• Buse JB, Bergenstal RM, Glass LC, et al. Use of twice-daily exenatide in basal insulin–treated patients with type 2 diabetes: a randomized, controlled trial. Ann Intern Med. 2011;154:103–112.
   PubMed Web of Science ®Google Scholar
• Riddle MC, Aronson R, Home P, et al. Adding once-daily lixisenatide for type 2 diabetes inadequately controlled by established basal insulin: a 24-week, randomized, placebo-controlled comparison (GetGoal-L). Diabetes Care. 2013 Sep;36(9):2489–2496.
   PubMed Web of Science ®Google Scholar
• Gough SC, Bode BW, Woo VC, et al. One-year efficacy and safety of a fixed combination of insulin degludec and liraglutide in patients with type 2 diabetes: results of a 26-week extension to a 26-week main trial. Diabetes Obes Metab. 2015;10:965–973.
   Web of Science ®Google Scholar
• Matthews D, Fulcher G, Perkovic V, et al. Efficacy and safety of canagliflozin, an inhibitor of sodium glucose co-transporter 2, added on to insulin therapy with or without oral agents in type 2 diabetes. Poster presented at: the 48th Annual Meeting of the European Association for the Study of Diabetes (EASD); 2012 Oct 1–5; Berlin.
   Google Scholar
• Eng C, Kramer CK, Zinman B, et al. Glucagon-like peptide-1 receptor agonist and basal insulin combination treatment for the management of type 2 diabetes: a systematic review and meta-analysis. The Lancet. 2014;384:2228–2234.
   PubMed Web of Science ®Google Scholar
• Inzucchi SE, Bergenstal RM, Buse JB, et al. Management of hyperglycaemia in type 2 diabetes, 2015: a patient-centred approach. Update to a position statement of the American diabetes association and the European association for the study of diabetes. Diabetologia. 2015b;58(3):429–442.
   PubMed Web of Science ®Google Scholar
• Garber AJ, Abrahamson MJ, Barzilay JI, et al. AACE/ACE comprehensive diabetes management algorithm 2015. Endocr Pract. 2015 Apr;21(4):438–447.
   PubMed Web of Science ®Google Scholar
• DeFronzo RA, Davidson JA, Del Prato S. The role of the kidneys in glucose homeostasis: a new path towards normalizing glycaemia. Diabetes Obes Metab. 2012 Jan;14(1):5–14. doi:10.1111/j.1463-1326.2011.01511.x.
   PubMed Web of Science ®Google Scholar
• Wilding JP, Woo V, Soler NG, et al. Long-term efficacy of dapagliflozin in patients with type 2 diabetes mellitus receiving high doses of insulin: a randomized trial. Ann Intern Med. 2012 Mar 20;156(6):405–415.
   PubMed Web of Science ®Google Scholar
• EMPA-REG BASALTM trial investigators, Rosenstock J, Jelaska A, Zeller C, et al. Impact of empagliflozin added on to basal insulin in type 2 diabetes inadequately controlled on basal insulin: a 78-week randomized, double-blind, placebo-controlled trial. Diabetes Obes Metab. 2015;17(10):936–948.
   PubMed Web of Science ®Google Scholar
• Schwartz S. Evidence-based practice use of incretin-based therapy in the natural history of diabetes. Postgrad Med. 2014;126(3):66–84.
   PubMed Web of Science ®Google Scholar
• Schwartz S. Synergy in diabetes treatment. Review in endocrinology. [updated 2008 Nov; Cited 2015Aug 2]. Available from: http://bmctoday.net/reviewofendo/2008/11/article.asp?f=review1108_07.php
   Google Scholar